• Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
Close Search
00
GBAF LogoGBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
GBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Top Stories

    Posted By Uma Rajagopal

    Posted on April 9, 2024

    Featured image for article about Top Stories

    Pfizer RSV shot meets goals in trial of high-risk adults under age 60

    By Michael Erman

    (Reuters) – Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved.

    Pfizer said it plans to submit its findings from the trial to seek expanded approval of the vaccine in adults ages 18 to 59, but did not give a time frame for when it expects the data to be considered by regulators.

    “This represents a real opportunity for an expansion to an age population in a risk population that wouldn’t normally see the availability of this vaccine so soon,” Dr. Iona Munjal, executive director of clinical vaccine R&D at Pfizer, said in an interview.

    The U.S. drugmaker last year launched Abrysvo for older adults and for pregnant women to protect their babies from the virus. GSK also launched its rival vaccine Arexvy in 2023 and has dominated the RSV vaccine market over the first season they were available.

    The British drugmaker is also looking to expand the age range for its shot and has already submitted data for adults ages 50 to 59 to the U.S. Food and Drug Administration. The FDA is expected to decide on whether to approve the label expansion by June 7, which could allow GSK to offer its shot in the younger age group later this year.

    Pfizer did not say whether it expects to be able to expand Abrysvo’s label in time for the 2024-25 respiratory virus season.

    RSV, which typically causes cold-like symptoms, is a leading cause of pneumonia in toddlers and older adults.

    The late-stage trial of Pfizer’s shot involved 681 adults aged 18 to 59 with conditions including asthma, diabetes, and chronic obstructive pulmonary disease that increase the risk from RSV. In this group, the immune response was non-inferior to the one observed in older adults, Pfizer said.

    The company said those with a higher risk profile represent 9.5% of U.S. adults 18 to 49 years of age and nearly a quarter of those between the ages of 50 and 64.

    Dr. David Boulware, an infections disease specialist at the University of Minnesota, said he was not sure most Americans who fit those high risk categories would need the shot.

    People who have had organ transplants, are undergoing chemotherapy for cancer, or are survivors of congenital disease would clinically benefit from the shot, he suggested.

    “The clinical benefit is likely going to be relatively low for most people,” he said.

    (Reporting by Michael Erman; Editing by Bill Berkrot)

    Recommended for you

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe